Shanghai Huaota Biopharmaceutical Co., Ltd.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS10
PHASE 3 / 2-33
RECRUITING5
READOUTS ≤12 MONTHS1
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| HB0034 NCT06231381 |
P2 | Recruiting | Generalized Pustular Psoriasis (GPP) | 33 | 2025-02-13 |
| HB0036 NCT05417321 |
P1/2 | Recruiting | Advanced Solid Tumor; NSCLC | 80 | 2025-08-01 |
| HB0052 Injection NCT06992687 |
P1/2 | Enrolling by invitation | Solid Tumors | 30 | 2025-09-30 |
| HB0043-HS-0-01 NCT06895499 |
P1/2 | Recruiting | Hidradenitis Suppurativa | 15 | 2026-01-30 |
| HB0043 NCT07449156 |
P1/2 | Not yet recruiting | Acne Vulgaris | 21 | 2026-10-27 |
| HB0056 NCT07899996 |
P1/2 | Recruiting | Asthma | 160 | 2027-08-01 |
| HB0056 NCT07909655 |
P2 | Not yet recruiting | Idiopathic Pulmonary Fibrosis (IPF) | 75 | 2028-01 |
| Pemetrexed injection NCT07383116 |
P3 | Not yet recruiting | Non Squamous Non-small Cell Lung Cancer | 500 | 2028-04-10 |
| Carboplatin Injection NCT07360132 |
P3 | Not yet recruiting | Squamous Non-small Cell Lung Cancer | 480 | 2028-04-10 |
| HB0025 Injection NCT07902999 |
P3 | Recruiting | First-line pMMR Endometrial Cancer | 333 | 2029-04-23 |